K
LIVE

Serial Number

99112933

Owner

Whitehawk Therapeutics, Inc.

Attorney

Aaron D. Hendelman

Filing Date

Mar 31, 2025

Add to watchlist:

No watchlists yet
View on USPTO

K Trademark

Serial Number: 99112933

K is a trademark filed by Whitehawk Therapeutics, Inc. on March 31, 2025. The trademark is classified under Class 5 (Pharmaceuticals), Class 42 (Computer & Scientific). The application is currently pending registration.

Owner Contact Info

Whitehawk Therapeutics, Inc. (2 trademarks)

2 Headquarters Plaza
Morristown, NJ 07960

Entity Type: 03

Trademark Details

Filing Date

March 31, 2025

Registration Date

Not Registered

Published for Opposition

September 23, 2025

Goods & Services

Pharmaceutical preparations for the treatment and prevention of cancer; pharmaceutical preparations for precision oncology; pharmaceutical preparations for the purpose of molecular profiling of tumors to identify targetable alterations; pharmaceutical preparations, namely, a drug formulation comprising antibody-drug conjugates (ADCs) for use in the field of oncology; pharmaceutical preparations, namely, a drug formulation comprising antibody-drug conjugates (ADCs) for use treating GI cancer, prostate cancer, cancer of the head and neck, endometrial cancer, cervical cancer, breast cancer, pancreatic cancer, central nervous system (CNS) tumors, solid tumors, non-small cell lung cancer (NSCLC), and ovarian cancer

Medical and scientific research in relation to precision oncology; medical and scientific research in relation to antibody-drug conjugates (ADCs) in the field of oncology; medical and scientific research for the purpose of molecular profiling of tumors to identify targetable alterations; medical and pharmaceutical research services; pharmaceutical research and development; providing medical and scientific research information in the field of pharmaceuticals and clinical trials; medical and scientific research, namely, conducting clinical trials for others; laboratory research services relating to pharmaceuticals; scientific and technological services, namely, scientific research services in the field of process development, validation, qualification, and manufacturing of pharmaceuticals and biopharmaceuticals; scientific research and technological services consultation services in the field of development, manufacturing and testing of pharmaceuticals and biopharmaceuticals; providing product research and development in the pharmaceutical field for purposes of drug discovery process development, drug discovery validation, drug discovery qualification, and drug discovery manufacturing of pharmaceuticals and biopharmaceuticals; scientific research and technological consultation services in the field of pharmaceutical research and pharmacology; custom development of pharmaceutical, biopharmaceutical and chemical products; providing evaluation and testing for pharmaceutical, biopharmaceutical and chemical products, and medical devices featuring testing for safety, toxicity, content, identity, purity, configuration and function for others, using chemical, in vitro or in vivo assays, analyses and models; pre-clinical and non-clinical evaluation and testing of pharmaceutical, biopharmaceutical and chemical products performed primarily using animals and other biological models; pharmaceutical, biopharmaceutical, and chemical research and development for others; pharmaceutical research in the field of oncology; pharmaceutical research in relation to GI cancer, prostate cancer, cancer of the head and neck, endometrial cancer, cervical cancer, breast cancer, pancreatic cancer, central nervous system (CNS) tumors, solid tumors, non-small cell lung cancer (NSCLC), and ovarian cancer

Filing History

NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED
Mar 10, 2026 EXRA
SOU EXTENSION 1 GRANTED
Mar 9, 2026 EX1G
SOU EXTENSION 1 FILED
Mar 9, 2026 EXT1
SOU TEAS EXTENSION RECEIVED
Mar 9, 2026 EEXT
NOA E-MAILED - SOU REQUIRED FROM APPLICANT
Nov 18, 2025 NOAM
OFFICIAL GAZETTE PUBLICATION CONFIRMATION E-MAILED
Sep 23, 2025 NPUB
PUBLISHED FOR OPPOSITION
Sep 23, 2025 PUBO
NOTIFICATION OF NOTICE OF PUBLICATION E-MAILED
Sep 17, 2025 NONP
APPROVED FOR PUB - PRINCIPAL REGISTER
Aug 21, 2025 CNSA
EXAMINER'S AMENDMENT ENTERED
Aug 21, 2025 XAEC
NOTIFICATION OF EXAMINERS AMENDMENT E-MAILED
Aug 21, 2025 GNEN
EXAMINERS AMENDMENT E-MAILED
Aug 21, 2025 GNEA
EXAMINERS AMENDMENT -WRITTEN
Aug 21, 2025 CNEA
ASSIGNED TO EXAMINER
Aug 20, 2025 DOCK
NEW APPLICATION OFFICE SUPPLIED DATA ENTERED
Aug 13, 2025 NWOS
APPLICATION FILING RECEIPT MAILED
Mar 31, 2025 MAFR
NEW APPLICATION ENTERED
Mar 31, 2025 NWAP